1,913
Participants
Start Date
September 30, 2005
Primary Completion Date
December 31, 2008
Study Completion Date
April 30, 2009
lenalidomide
Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
dexamethasone
Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
St. Vincent's Comprehensive Cancer Center, New York
NY Presbyterian Hospital/Weill Medical College-Cornell University, New York
New York Medical Center, MBCCOP, The Bronx
SUNY Health Science Center - Brooklyn, Brooklyn
North Shore Hematology/Oncology Associates, PC, East Setauket
SUNY Upstate Medical University, Syracuse
Western Pennsylvania Cancer Institute, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
University of Pennsylvania Cancer Center, Philadelphia
Delaware Clinical & Laboratory Physicians, PA, Newark
Center for Cancer And Blood Disorders, Bethesda
Medical College of Virginis, North Hospital, Richmond
Carolinas Hematology-Oncology Associates, Charlotte
South Carolina Oncology Assoc, Columbia
Charleston Hematology/Oncology P.A., Charleston
Medical University of South Carolina, Charleston
Emory University, Atlanta
Kaiser Permanente Medical Group, San Diego
University of Miami Medical School, Miami
Mount Sinai Comprehensive Cancer Center, Miami Beach
The Palm Beach Cancer Institute, West Palm Beach
Gulf Coast Oncology, St. Petersburg
Jackson Oncology Associates, Jackson
Mid Ohio Oncology & Hematology, Inc., Columbus
Oncology Alliance, Milwaukee
Marshfield Clinic, Marshfield
Gunderson Clinic, La Crosse
Mayo Clinic Cancer Center, Rochester
Avera Research Institute, Sioux Falls
Deaconess Billings Clinic, Billings
Siteman Cancer Center, St Louis
Wichita CCOP, Wichita
Methodist Cancer Center, Omaha
Ochsner Clinic Foundation, New Orleans
MD Anderson Cancer Center, Houston
Rocky Mountain Cancer Center-Midtown, Denver
Huntsman Cancer Institute, Salt Lake City
Intermountain Hematology/Oncology, Salt Lake City
Mayo Clinic, Scottsdale
Nevada Cancer Center, Las Vegas
Cedar Sinai Medical CenterDept of Medicine, Los Angeles
Scripps Cancer Center, La Jolla
Kaiser Permanente Medical Center, Vallejo
Alta Bates Cancer Center, Berkeley
Kaiser Permanente Northwest RegionCenter for Health Research, Portland
Swedish Cancer Institute, Seattle
Fred Hutchinson Cancer Research Center, Seattle
Stanford Cancer Center, Stanford
University of ColoradoHealth Science Center, Aurora
Yale University School of Medicine, New Haven
Hematology Oncology, PC, Stamford
H Lee Moffitt Cancer Center, Tampa
Northwestern University Med CtrDivision of Hem/Onc, Chicago
Rush Cancer Institute, Chicago
Indiana Univ Cancer Center Bone Marrow Transplantation Program Indiana Cancer Research Institute, Indianapolis
University of Kansas Medical Center, Kansas City
University of Maryland Medical Center Greenbaum Cancer Ctr, Baltimore
Dana-Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center-Norris Cotton Cancer Center, Lebanon
The Cancer Center at Hackensack University Medical Center, Hackensack
Wake Forest University School of Medicine, Winston-Salem
Dakota Cancer Institute, Fargo
University of Texas Southwestern Medical Center, Dallas
University of Calgary, Calgary
Cross Cancer Institute, Edmonton
Leukemia/BMT Program of BCDiv of Hem, Vancouver Gen Hosp, Vancouver
Dalhousie University Queen Elizabeth II Health Services Centre, Halifax
Princess Margaret Hospital, Toronto
McGill University, Montreal
Lead Sponsor
Prologue Research International
INDUSTRY
Celgene Corporation
INDUSTRY